Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2018 Jul 6;16(1):134.
doi: 10.1186/s12955-018-0962-3.

Assessing patients' acceptance of their medication to reveal unmet needs: results from a large multi-diseases study using a patient online community

Jérémy Lambert  1 , Michael Chekroun  2 , Hélène Gilet  1   3 , Catherine Acquadro  4 , Benoit Arnould  1
Affiliations
Observational Study

Assessing patients' acceptance of their medication to reveal unmet needs: results from a large multi-diseases study using a patient online community

Jérémy Lambert et al. Health Qual Life Outcomes. .

Abstract

Background: Patients with chronic conditions are required to take long-term treatments for their disease itself or to prevent any potential health risks. Measuring patient acceptance of their medication should help to better understand and predict patients' behavior toward treatment. This study aimed to describe the level of patient acceptance toward various long-term treatments in real life using an online patient community.

Methods: This was an observational, cross-sectional study conducted through the French Carenity platform. All Carenity patient members were invited to complete an online questionnaire including the 25-item ACCEptance by the Patients of their Treatment (ACCEPT©) questionnaire. ACCEPT© measures patient acceptance toward their medication and includes one general acceptance dimension (Acceptance/General) and six treatment-attribute specific dimensions (scores 0-100; lowest to highest acceptance): Acceptance/Medication Inconvenience, Acceptance/Long-term Treatment, Acceptance/Regimen Constraints, Acceptance/Side effects, Acceptance/Effectiveness, and Acceptance/Numerous Medications. Patients included in the analysis were treated adults experiencing any chronic diseases and who responded to at least one ACCEPT© item.

Results: Among the 4193 patients included in the analysis, more than 270 chronic diseases were represented, amidst which 19 included more than 30 patients. Mean ACCEPT© Acceptance/General score for those 19 diseases were 61.2 (SD = 31.9) for type 1 diabetes, 59.8 (SD = 32.3) for asthma, 56.3 (SD = 34.3) for hypertension, 52.0 (SD = 32.2) for chronic obstructive pulmonary disease, 51.7 (SD = 27.0) for epilepsy, 50.1 (SD = 33.1) for bipolar disorder, 49.9 (SD = 33.1) for type 2 diabetes, 48.6 (SD = 31.6) for multiple sclerosis, 46.1 (SD = 34.5) for Crohn's disease/ulcerative colitis, 44.3 (SD = 31.5) for depression, 42.8 (SD = 31.5) for lupus, 42.3 (SD = 33.0) for arthrosis, 41.8 (SD = 32.6) for Parkinson's disease, 40.5 (SD = 32.2) for rheumatoid arthritis, 38.6 (SD = 31.7) for breast cancer, 36.4 (SD = 36.4) for myocardial infarction, 35.8 (SD = 32.0) for ankylosing spondylitis, 34.1 (SD = 32.3) for psoriasis, and 33.7 (SD = 31.7) for fibromyalgia.

Conclusions: This first of its kind study enabled ACCEPT© data to be collected in real life for a variety of chronic diseases. These data may help in evaluating and interpreting levels of acceptance in future studies and provide valuable insights about patient priorities and current unmet needs.

Keywords: Acceptance; Chronic disease; Convenience; Observational study; Questionnaire; Risk/benefit assessment; Tolerability.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

As members of the Carenity platform, patients involved in this study were informed as they registered on the platform, and have consented expressly and specifically to the collection, handling and keeping of their personal and health data. They were also informed before starting the survey of the purpose of the study. The procedures followed for this study were in accordance with the French Law 78–17 of 6 January 1978 and its later amendments and with the 1964 Helsinki declaration and its later amendments.

Consent for publication

Not applicable.

Competing interests

BA, HG and JL were employees of Mapi at the time of the study. CA was a consultant, now employee of Mapi. MC is founder and CEO of Carenity.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Patient population
Fig. 2
Fig. 2
ACCEPT Acceptance/General score per disease
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Curtin F, Schulz P. Assessing the benefit: risk ratio of a drug--randomized and naturalistic evidence. Dialogues Clin Neurosci. 2011;13:183–190. - PMC - PubMed
    1. Sackett DL, Haynes RB. Compliance with therapeutic regimens. 1976.
    1. daCosta DiBonaventura M, Copher R, Basurto E, Faria C, Lorenzo R. Patient preferences and treatment adherence among women diagnosed with metastatic breast cancer. Am Health Drug Benefits. 2014;7:386–396. - PMC - PubMed
    1. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119:3028–3035. doi: 10.1161/CIRCULATIONAHA.108.768986. - DOI - PubMed
    1. Gottlieb H. Medication nonadherence: finding solutions to a costly medical problem. Drug Benefit Trends. 2000;12:57–62.

Publication types